KR102642811B1 - Composition for relieving hangover based on soybean curd residue micro-powder - Google Patents
Composition for relieving hangover based on soybean curd residue micro-powder Download PDFInfo
- Publication number
- KR102642811B1 KR102642811B1 KR1020210006874A KR20210006874A KR102642811B1 KR 102642811 B1 KR102642811 B1 KR 102642811B1 KR 1020210006874 A KR1020210006874 A KR 1020210006874A KR 20210006874 A KR20210006874 A KR 20210006874A KR 102642811 B1 KR102642811 B1 KR 102642811B1
- Authority
- KR
- South Korea
- Prior art keywords
- powder
- composition
- weight
- relieving
- okara
- Prior art date
Links
- 239000000843 powder Substances 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 206010019133 Hangover Diseases 0.000 title claims abstract description 26
- 235000013527 bean curd Nutrition 0.000 title description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 71
- 230000000694 effects Effects 0.000 claims abstract description 34
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims abstract description 31
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims abstract description 31
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims abstract description 30
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims abstract description 30
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 20
- 239000012138 yeast extract Substances 0.000 claims abstract description 20
- 229920002261 Corn starch Polymers 0.000 claims abstract description 16
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 239000008120 corn starch Substances 0.000 claims abstract description 16
- 229940052016 turmeric extract Drugs 0.000 claims abstract description 12
- 235000020240 turmeric extract Nutrition 0.000 claims abstract description 12
- 239000008513 turmeric extract Substances 0.000 claims abstract description 12
- 229940096421 milk thistle extract Drugs 0.000 claims description 15
- 235000020727 milk thistle extract Nutrition 0.000 claims description 15
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000007963 capsule composition Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000010841 Silybum marianum Nutrition 0.000 abstract description 11
- 241000320380 Silybum Species 0.000 abstract description 10
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 235000012754 curcumin Nutrition 0.000 description 14
- 229940109262 curcumin Drugs 0.000 description 14
- 239000004148 curcumin Substances 0.000 description 14
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 14
- 244000163122 Curcuma domestica Species 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 235000003373 curcuma longa Nutrition 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 235000003392 Curcuma domestica Nutrition 0.000 description 11
- 235000013976 turmeric Nutrition 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 108010073771 Soybean Proteins Proteins 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000003028 enzyme activity measurement method Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000013322 soy milk Nutrition 0.000 description 3
- 229940001941 soy protein Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 2
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 2
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- -1 etc.) Chemical compound 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- HMJSBVCDPKODEX-NXZHAISVSA-N (1e,6e)-1,7-bis(3,4-dimethoxyphenyl)hepta-1,6-diene-3,5-dione Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(OC)C(OC)=C1 HMJSBVCDPKODEX-NXZHAISVSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 244000272459 Silybum marianum Species 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021075 protein intake Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Agronomy & Crop Science (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
본 개시물에는 콩비지 미세분말 기반의 숙취 해소용 조성물이 개시된다. 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 분말을 포함하여 혈액 내 알코올 함량을 감소시키고 알코올탈수소효소 (ADH) 및 알데히드탈수소효소 (ALDH)의 활성을 증진시키는 효과가 우수하다.The present disclosure discloses a composition for relieving hangovers based on okara fine powder. The composition contains turmeric extract powder, okara powder, yeast extract powder, corn starch, and milk thistle powder, which has the effect of reducing alcohol content in the blood and enhancing the activities of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). is excellent.
Description
본 개시물에는 콩비지 미세분말 기반의 숙취 해소용 조성물이 개시된다.The present disclosure discloses a composition for relieving hangovers based on okara fine powder.
숙취 현상은 간세포와 체내에 축적된 알코올 (alcohol) 및 아세트알데히드 (acetaldehyde)의 작용에 의해 발생한다. 정상적인 상태에서 소량의 알코올을 섭취할 경우 간 장내로 들어온 에탄올은 세포 사이토졸 (cytosol) 내의 알코올탈수소효소 (alcohol dehydrogenase, ADH)와 알데히드탈수소효소 (aldehyde dehydrogenase, ALDH)의 작용에 의해 아세테이트 (acetate)로 전환되고, 이는 순환계를 통해 간세포 밖으로 배설된다. 이중 특히 에탄올의 최초 대사산물인 아세트알데히드는 에탄올에 비해 반응성이 매우 높고 독성이 강하여 알코올성 간 장애의 주원인 물질인 것으로 알려져 있다.The hangover phenomenon is caused by the action of alcohol and acetaldehyde accumulated in liver cells and the body. When a small amount of alcohol is consumed under normal conditions, the ethanol that enters the liver and intestines is converted to acetate by the action of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cell cytosol. converted to , which is excreted out of the liver cells through the circulatory system. Among these, acetaldehyde, the first metabolite of ethanol, is known to be a major cause of alcoholic liver failure as it is highly reactive and highly toxic compared to ethanol.
일 측면에서, 본 개시물은 콩비지 미세분말 기반의 숙취 해소용 조성물을 제공하는 것을 목적으로 한다.In one aspect, the purpose of the present disclosure is to provide a composition for relieving hangovers based on okara fine powder.
일 측면에서, 본 개시물은 강황 및 콩비지를 유효성분으로 포함하는 숙취 해소용 조성물을 제공한다.In one aspect, the present disclosure provides a composition for relieving a hangover containing turmeric and okara as active ingredients.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 강황 및 콩비지를 각각 2 내지 5 중량% 및 25 내지 40 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include 2 to 5% by weight and 25 to 40% by weight of turmeric and okara, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 효모, 옥수수전분 및 밀크씨슬을 더 포함하는 것일 수 있다.In an exemplary embodiment, the composition may further include yeast, corn starch, and milk thistle.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 효모, 옥수수전분 및 밀크씨슬을 각각 25 내지 40 중량%, 15 내지 25 중량% 및 3 내지 6 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may contain 25 to 40% by weight, 15 to 25% by weight, and 3 to 6% by weight of yeast, corn starch, and milk thistle, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include turmeric extract powder, okara powder, yeast extract powder, corn starch, and milk thistle extract powder.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 1 : 8 내지 10 : 8 내지 10 : 6 내지 8 : 1 내지 2의 중량비로 포함하는 것일 수 있다.In an exemplary embodiment, the composition includes turmeric extract powder, okara powder, yeast extract powder, corn starch, and milk thistle extract powder in a weight ratio of 1:8 to 10:8 to 10:6 to 8:1 to 2. It may include
예시적인 일 구현예에서, 상기 조성물은 혈액 내 알코올 함량을 감소시키는 것일 수 있다.In one exemplary embodiment, the composition may reduce alcohol content in the blood.
예시적인 일 구현예에서, 상기 조성물은 알코올탈수소효소 (ADH) 및 알데히드탈수소효소 (ALDH)의 활성을 증진시키는 것일 수 있다.In an exemplary embodiment, the composition may enhance the activities of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
다른 측면에서, 본 개시물은 숙취 해소용 조성물을 포함하는 숙취 해소용 건강보조식품을 제공한다.In another aspect, the present disclosure provides a health supplement for relieving hangovers, including a composition for relieving hangovers.
예시적인 일 구현예에서, 상기 건강보조식품은 액상, 환제, 정제, 과립제, 산제 또는 캡슐제 제형을 갖는 것일 수 있다.In an exemplary embodiment, the health supplement may have a liquid, pill, tablet, granule, powder, or capsule formulation.
일 측면에서, 본 개시물에 개시된 기술은 콩비지 미세분말 기반의 숙취 해소용 조성물을 제공하는 효과가 있다.In one aspect, the technology disclosed in the present disclosure has the effect of providing a composition for relieving hangovers based on okara fine powder.
도 1은 일 실험예에 따른 커큐민 복합체와 콩비지 혼합물의 HPLC 분석 전처리 과정을 나타낸 것이다.
도 2는 일 실험예에 따른 커큐민 복합체와 콩비지 혼합물의 HPLC 분석 전처리 사진을 나타낸 것이다.
도 3은 일 실험예에 따른 HPLC 분석 결과 440 nm chromatogram을 나타낸 것이다.
도 4는 일 실험예에 따른 in vitro 알코올탈수소효소 (ADH, Alcohol Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.
도 5는 일 실험예에 따른 in vitro 알데히드탈수소효소 (ALDH, Aldehyde Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.
도 6은 일 실험예에 따른 in vivo 혈중 알코올 농도 측정 결과를 나타낸 것이다.
도 7은 일 실험예에 따른 in vivo 알코올탈수소효소 (ADH, Alcohol Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.
도 8은 일 실험예에 따른 in vivo 알데히드탈수소효소 (ALDH, Aldehyde Dehydrogenase) 효소 활성 측정 결과를 나타낸 것이다.Figure 1 shows the pretreatment process for HPLC analysis of a mixture of curcumin complex and okara according to an experimental example.
Figure 2 shows a photo of pretreatment for HPLC analysis of a mixture of curcumin complex and okara according to an experimental example.
Figure 3 shows a 440 nm chromatogram as a result of HPLC analysis according to an experimental example.
Figure 4 shows the results of in vitro alcohol dehydrogenase (ADH) enzyme activity measurement according to an experimental example.
Figure 5 shows the results of in vitro aldehyde dehydrogenase (ALDH) enzyme activity measurement according to an experimental example.
Figure 6 shows the results of in vivo blood alcohol concentration measurement according to an experimental example.
Figure 7 shows the results of in vivo alcohol dehydrogenase (ADH) enzyme activity measurement according to an experimental example.
Figure 8 shows the results of measuring in vivo aldehyde dehydrogenase (ALDH) enzyme activity according to an experimental example.
이하, 본 개시물을 상세히 설명한다.Hereinafter, the present disclosure will be described in detail.
일 측면에서, 본 개시물은 강황 및 콩비지를 유효성분으로 포함하는 숙취 해소용 조성물을 제공한다.In one aspect, the present disclosure provides a composition for relieving a hangover containing turmeric and okara as active ingredients.
강황 (Curcuma longa)은 생강과에 속하는 식물로서, 약용으로 쓰이는 뿌리줄기 쪽에 여러 가지 유용 성분이 함유되어 있으며, 가장 대표적인 성분으로는 커큐민이 있다. 상기 강황은 강황의 뿌리줄기로서, 예시적인 일 구현예에서, 상기 강황은 강황의 분말, 추출물 또는 추출물의 분말인 것일 수 있다.Turmeric ( Curcuma longa ) is a plant belonging to the ginger family. The rhizome used for medicinal purposes contains various useful ingredients, the most representative ingredient being curcumin. The turmeric is a rhizome of turmeric, and in an exemplary embodiment, the turmeric may be a powder, extract, or powder of an extract of turmeric.
상기 강황 추출물은 당해 기술분야에 알려진 방법에 따라 직접 추출하여 제조할 수도 있고, 시판의 제품을 구입하여 사용할 수도 있다. 예시적인 일 구현예에서, 강황 추출물은 물, 탄소수 1 내지 4의 알코올 (예컨대, 메탄올, 에탄올, 프로판올, 부탄올 등), 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드 (DMF), 염화메틸렌, 디메틸설폭사이드 (DMSO), 글리세린, 부틸렌글리콜, 프로필렌글리콜, 디프로필렌글리콜, 메틸렌클로라이드 및 디에틸에테르로 이루어진 군에서 선택되는 1 이상의 용매로 추출한 것일 수 있다.The turmeric extract can be manufactured by direct extraction according to a method known in the art, or it can be used by purchasing a commercially available product. In an exemplary embodiment, the turmeric extract is water, alcohol having 1 to 4 carbon atoms (e.g., methanol, ethanol, propanol, butanol, etc.), ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, One or more solvents selected from the group consisting of N, N-dimethylformamide (DMF), methylene chloride, dimethyl sulfoxide (DMSO), glycerin, butylene glycol, propylene glycol, dipropylene glycol, methylene chloride, and diethyl ether. It may have been extracted.
콩비지는 두부를 만들 때 두유를 짜고 남은 부산물을 의미한다. 예를 들어, 상기 콩비지는 콩단백에서 두유를 짜고 남은 부산물을 의미하는 것으로, 콩단백에서 수용성 단백질을 제거한 것일 수 있다. 상기 콩단백은 콩에서 기름을 빼고 남은 부산물을 의미하는 것으로, 착유 공정은 당업자가 당해 기술분야에 알려진 방법을 적절하게 선택하여 실시할 수 있다. 예를 들어, 상기 콩단백은 압착 콩단백으로, 유기용매 사용 없이 압착 방식으로, 예컨대 상온 압착 방식으로 콩에서 기름을 빼고 남은 부산물인 것일 수 있다.Bean curd refers to the by-product left over from squeezing soy milk when making tofu. For example, the soybean curd refers to a by-product remaining after extracting soymilk from soybean protein, and may be obtained by removing the water-soluble protein from the soybean protein. The soy protein refers to the by-product remaining after removing the oil from the soybean, and the milking process can be performed by a person skilled in the art by appropriately selecting a method known in the art. For example, the soy protein may be a compressed soy protein, which is a by-product remaining after oil is removed from soybeans by pressing without using an organic solvent, for example, by pressing at room temperature.
콩비지는 많은 양의 수용성 물질이 빠져 나간 상태이나, 양질의 단백질과 풍부한 섬유소를 비롯해 인체에 필요한 영양성분들을 포함하고 있다. 단백질 섭취량에 따른 체중 증가량의 비율을 나타내는 값인 단백질 효율비 (protein efficiency ratio, PER)가 대두, 두유 및 두부 중에서 가장 높은 우수한 단백질 자원이다. 또한, 콩비지는 여성 호르몬 에스트로겐과 유사 작용을 하는 이소플라본 (phytoestrogen)을 고함유하여 폐경기 증후군의 예방 및 치료에도 활용이 가능하다.Although a large amount of water-soluble substances have been removed from the soybean curd, it contains nutrients necessary for the human body, including high-quality protein and abundant fiber. It is an excellent protein resource with the highest protein efficiency ratio (PER), which is a value representing the ratio of weight gain based on protein intake, among soybeans, soymilk, and tofu. In addition, okara is high in isoflavones (phytoestrogens), which act similarly to the female hormone estrogen, so it can be used to prevent and treat menopausal syndrome.
예시적인 일 구현예에서, 상기 콩비지는 건조 및 분쇄한 것일 수 있다.In an exemplary embodiment, the soybean curd may be dried and ground.
예시적인 일 구현예에서, 상기 콩비지는 두부 제조 후 남은 부산물을 열풍건조한 후 미세분말화한 것일 수 있다.In one exemplary embodiment, the soybean curd may be obtained by drying by-products remaining after manufacturing tofu with hot air and then powdering them into fine powder.
예시적인 일 구현예에서, 상기 콩비지는 500 내지 2,000 mesh의 크기를 갖는 것일 수 있다. 다른 예시적인 일 구현예에서, 상기 콩비지는 500 mesh 이상, 600 mesh 이상, 700 mesh 이상, 800 mesh 이상, 900 mesh 이상 또는 1,000 mesh 이상이고, 2,000 mesh 이하, 1,900 mesh 이하, 1,800 mesh 이하, 1,700 mesh 이하, 1,600 mesh 이하, 1,500 mesh 이하, 1,400 mesh 이하, 1,300 mesh 이하, 1,200 mesh 이하 1,100 mesh 이하 또는 1,000 mesh 이하의 크기를 갖는 것일 수 있다. 예컨대, 상기 콩비지는 900 내지 1,100 mesh 또는 1,000 mesh의 크기를 갖는 것이 바람직할 수 있다.In one exemplary embodiment, the soybean curd may have a size of 500 to 2,000 mesh. In another exemplary embodiment, the soybean curd is 500 mesh or more, 600 mesh or more, 700 mesh or more, 800 mesh or more, 900 mesh or more, or 1,000 mesh or more, 2,000 mesh or less, 1,900 mesh or less, 1,800 mesh or less, 1,700 mesh. It may have a size of 1,600 mesh or less, 1,500 mesh or less, 1,400 mesh or less, 1,300 mesh or less, 1,200 mesh or less, 1,100 mesh or less, or 1,000 mesh or less. For example, it may be desirable for the soybean curd to have a size of 900 to 1,100 mesh or 1,000 mesh.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 강황 및 콩비지를 각각 2 내지 5 중량% 및 25 내지 40 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include 2 to 5% by weight and 25 to 40% by weight of turmeric and okara, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 강황을 2 중량% 이상, 3 중량% 이상 또는 4 중량% 이상이고, 5 중량% 이하, 4 중량% 이하 또는 3 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains 2% by weight or more, 3% by weight or more, or 4% by weight or more, and 5% by weight or less, 4% by weight or less, or 3% by weight or less of turmeric based on the total weight of the composition. It may be.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 콩비지를 25 중량% 이상, 28 중량% 이상, 31 중량% 이상 또는 34 중량% 이상이고, 40 중량% 이하, 37 중량% 이하, 34 중량% 이하 또는 31 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains at least 25% by weight, at least 28% by weight, at least 31% by weight, or at least 34% by weight, and at least 40% by weight, at most 37% by weight, at least 34% by weight, based on the total weight of the composition. It may contain less than % by weight or less than 31% by weight.
예시적인 일 구현예에서, 상기 조성물은 효모, 옥수수전분 및 밀크씨슬을 더 포함하는 것일 수 있다.In an exemplary embodiment, the composition may further include yeast, corn starch, and milk thistle.
효모는 빵, 맥주, 포도주 등을 만드는 데 사용되는 미생물로서, 곰팡이나 버섯 무리이지만 균사가 없고, 광합성능이나 운동성도 가지지 않는 단세포 생물을 총칭한다. 예시적인 일 구현예에서, 상기 효모는 건조 효모 분말, 효모 추출물 또는 효모 추출 분말인 것일 수 있다.Yeast is a microorganism used to make bread, beer, wine, etc. It is a group of molds or mushrooms, but it is a general term for single-celled organisms that do not have hyphae and do not have photosynthesis or motility. In an exemplary embodiment, the yeast may be dry yeast powder, yeast extract, or yeast extract powder.
상기 건조 효모 분말은 건조 효모의 분말을 의미하는 것으로, 건조 효모는 효모가 수분이 많아 부패하기 쉬우므로 저장이 가능하도록 건조시킨 효모를 의미한다. 건조 효모는 효모가 죽지 않도록 건조시켜야 하며, 예시적인 일 구현예에서, 저온에서 통풍하여 건조시키는 방법, 약 30 ℃의 온도에서 8시간 동안 건조시키는 방법, 수평 방향으로 회전하는 건조통 속에서 통풍 건조시키는 방법 등 당해 기술분야에 알려진 방법에 따라 효모를 건조시킬 수 있으며, 열에 의한 효모의 사멸을 억제하기 위해 동결건조하는 것이 바람직할 수 있다.The dry yeast powder refers to the powder of dry yeast. Dry yeast refers to yeast that has been dried to enable storage because yeast has a lot of moisture and is easily perishable. Dry yeast must be dried to prevent the yeast from dying, and in an exemplary embodiment, drying by ventilation at a low temperature, drying at a temperature of about 30° C. for 8 hours, and drying by ventilation in a drying tank rotating in a horizontal direction. Yeast can be dried according to methods known in the art, such as methods known in the art, and freeze-drying may be preferable to suppress death of yeast due to heat.
상기 효모 추출물은 효모로부터 당해 기술분야에 알려진 방법에 따라 직접 추출하여 제조할 수도 있고, 시판의 제품을 구입하여 사용할 수도 있다. 예시적인 일 구현예에서, 상기 효모 추출물의 제조는 먼저 건조 효모에 효모 무게의 5배 내지 10배에 해당하는 물을 가하고 상온에서 1 내지 5 시간 동안 배양하여 효모를 활성화시킨 다음, 50 내지 88 ℃에서 0.5 내지 5 시간 동안 추출한 후 여과하여 효모 추출물을 얻을 수 있다. 또한, 수득한 효모 추출물을 고형분의 함량이 10% (w/v) 이상이 되도록 농축하고, 농축한 효모 추출물을 한외여과막으로 분자량 5,000 내지 20,000 달톤의 여과막이 장착된 시스템에서 여과한 후 이를 다시 농축하고 동결건조하여 효모 추출물을 얻을 수 있다.The yeast extract can be prepared by directly extracting yeast from yeast according to a method known in the art, or it can be used by purchasing a commercially available product. In an exemplary embodiment, the preparation of the yeast extract is performed by first adding water equivalent to 5 to 10 times the weight of the yeast to dry yeast, cultivating the yeast at room temperature for 1 to 5 hours, and then activating the yeast at 50 to 88 ° C. A yeast extract can be obtained by extracting for 0.5 to 5 hours and then filtering. In addition, the obtained yeast extract was concentrated to a solid content of 10% (w/v) or more, the concentrated yeast extract was filtered using an ultrafiltration membrane in a system equipped with a filtration membrane with a molecular weight of 5,000 to 20,000 daltons, and then concentrated again. Yeast extract can be obtained by freeze-drying.
상기 효모 추출 분말은 효모 추출물의 분말을 의미한다.The yeast extract powder refers to a powder of yeast extract.
예시적인 일 구현예에서, 상기 옥수수전분은 옥수수전분 분말인 것일 수 있다.In one exemplary embodiment, the corn starch may be corn starch powder.
밀크씨슬 (Silybum marianum)은 국화과 식물로서, 열매와 씨에는 플라보노리그난이 함유되어 있으며 주요 구성 성분을 총칭하여 실리마린이라고 한다. 실리마린은 간 건강에 도움을 주는 것으로 알려져 있다. 예시적인 일 구현예에서, 상기 밀크씨슬은 밀크씨슬 분말, 밀크씨슬 추출물 또는 밀크씨슬 추출 분말인 것일 수 있다. 상기 밀크씨슬 추출 분말은 밀크씨슬 추출물의 분말을 의미한다. 예시적인 일 구현예에서, 상기 밀크씨슬은 밀크씨슬 종자의 분말, 추출물 또는 추출물의 분말인 것일 수 있다. Milk thistle ( Silybum marianum ) is a plant in the Asteraceae family. Its fruits and seeds contain flavonolignans, and its major components are collectively called silymarin. Silymarin is known to help liver health. In an exemplary embodiment, the milk thistle may be milk thistle powder, milk thistle extract, or milk thistle extract powder. The milk thistle extract powder refers to the powder of milk thistle extract. In an exemplary embodiment, the milk thistle may be a powder, extract, or powder of an extract of milk thistle seeds.
상기 밀크씨슬 추출물은 당해 기술분야에 알려진 방법에 따라 직접 추출하여 제조할 수도 있고, 시판의 제품을 구입하여 사용할 수도 있다. 예시적인 일 구현예에서, 밀크씨슬 추출물은 물, 탄소수 1 내지 4의 알코올 (예컨대, 메탄올, 에탄올, 프로판올, 부탄올 등), 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N, N-디메틸포름아미드 (DMF), 염화메틸렌, 디메틸설폭사이드 (DMSO), 글리세린, 부틸렌글리콜, 프로필렌글리콜, 디프로필렌글리콜, 메틸렌클로라이드 및 디에틸에테르로 이루어진 군에서 선택되는 1 이상의 용매로 추출한 것일 수 있다.The milk thistle extract can be manufactured by direct extraction according to a method known in the art, or it can be used by purchasing a commercially available product. In an exemplary embodiment, the milk thistle extract is water, alcohol having 1 to 4 carbon atoms (e.g., methanol, ethanol, propanol, butanol, etc.), ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloroform. At least one selected from the group consisting of methane, N, N-dimethylformamide (DMF), methylene chloride, dimethyl sulfoxide (DMSO), glycerin, butylene glycol, propylene glycol, dipropylene glycol, methylene chloride, and diethyl ether. It may have been extracted with a solvent.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 효모, 옥수수전분 및 밀크씨슬을 각각 25 내지 40 중량%, 15 내지 25 중량% 및 3 내지 6 중량%로 포함하는 것일 수 있다.In an exemplary embodiment, the composition may contain 25 to 40% by weight, 15 to 25% by weight, and 3 to 6% by weight of yeast, corn starch, and milk thistle, respectively, based on the total weight of the composition.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 효모를 25 중량% 이상, 28 중량% 이상, 31 중량% 이상 또는 34 중량% 이상이고, 40 중량% 이하, 37 중량% 이하, 34 중량% 이하 또는 31 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains at least 25% by weight, at least 28% by weight, at least 31% by weight, or at least 34% by weight, and at least 40% by weight, at most 37% by weight, at least 34% by weight, based on the total weight of the composition. It may contain less than % by weight or less than 31% by weight.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 옥수수전분을 15 중량% 이상, 18 중량% 이상 또는 21 중량% 이상이고, 25 중량% 이하, 23 중량% 이하, 21 중량% 이하 또는 19 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains 15% by weight or more, 18% by weight or more, or 21% by weight or more, and 25% by weight or less, 23% by weight or less, or 21% by weight or less, based on the total weight of the composition. It may contain less than 19% by weight.
예시적인 일 구현예에서, 상기 조성물은 조성물 전체 중량을 기준으로 밀크씨슬을 3 중량% 이상, 4 중량% 이상 또는 5 중량% 이상이고, 6 중량% 이하, 5 중량% 이하 또는 4 중량% 이하로 포함하는 것일 수 있다.In an exemplary embodiment, the composition contains 3% by weight or more, 4% by weight or more, or 5% by weight or more, and 6% by weight or less, 5% by weight or less, or 4% by weight or less, based on the total weight of the composition. It may be included.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 포함하는 것일 수 있다.In an exemplary embodiment, the composition may include turmeric extract powder, okara powder, yeast extract powder, corn starch, and milk thistle extract powder.
예시적인 일 구현예에서, 상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 및 밀크씨슬 추출 분말을 1 : 8 내지 10 : 8 내지 10 : 6 내지 8 : 1 내지 2의 중량비로 포함하는 것일 수 있다.In an exemplary embodiment, the composition includes turmeric extract powder, okara powder, yeast extract powder, corn starch, and milk thistle extract powder in a weight ratio of 1:8 to 10:8 to 10:6 to 8:1 to 2. It may include
예시적인 일 구현예에서, 상기 조성물은 혈액 내 알코올 함량을 감소시키는 것일 수 있다.In one exemplary embodiment, the composition may reduce alcohol content in the blood.
예시적인 일 구현예에서, 상기 조성물은 알코올탈수소효소 (ADH) 및 알데히드탈수소효소 (ALDH)의 활성을 증진시키는 것일 수 있다.In an exemplary embodiment, the composition may enhance the activities of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
다른 측면에서, 본 개시물은 숙취 해소용 조성물을 포함하는 숙취 해소용 건강보조식품을 제공한다.In another aspect, the present disclosure provides a health supplement for relieving hangovers, including a composition for relieving hangovers.
예시적인 일 구현예에서, 상기 건강보조식품은 액상, 환제, 정제, 과립제, 산제 또는 캡슐제 제형을 갖는 것일 수 있다.In an exemplary embodiment, the health supplement may have a liquid, pill, tablet, granule, powder, or capsule formulation.
이하, 실시예를 통하여 본 개시물을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 개시물을 예시하기 위한 것으로서, 본 개시물의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present disclosure will be described in more detail through examples. It will be apparent to those skilled in the art that these examples are solely for illustrating the present disclosure, and that the scope of the present disclosure should not be construed as limited by these examples.
실시예. 숙취 해소용 조성물 제조Example. Manufacture of composition for relieving hangover
하기 표 1의 조성비에 따라 숙취 해소용 조성물을 제조하여 하기 실험예에서 사용하였다. 또한, 큐원㈜에서 상쾌환을 구입하여 이를 실시예 3의 양성 대조군으로 사용하였다.A composition for relieving hangovers was prepared according to the composition ratio in Table 1 below and used in the following experimental examples. In addition, EASY TOMORROW was purchased from Q1 Co., Ltd. and used as a positive control in Example 3.
실험예 1. 커큐민 복합체와 콩비지 혼합물의 성분 분석Experimental Example 1. Component analysis of curcumin complex and okara mixture
강황의 주성분인 커큐민 (Curcumin) 70 내지 80 중량%, 디메톡시커큐민 (demethoxycurcumin, DMC) 15 내지 25 중량% 및 비스디메톡시 커큐민 (bisdemethoxy curcumin, BDMC) 2.5 내지 6.5 중량%를 포함하는 커큐민 복합체 (Curcumin C3 complex)와 상기 커큐민 복합체에 콩비지 분말을 첨가한 콩비지 혼합물의 성분을 분석하여 비교하였다.Curcumin complex (Curcumin) containing 70 to 80% by weight of curcumin, the main component of turmeric, 15 to 25% by weight of demethoxycurcumin (DMC), and 2.5 to 6.5% by weight of bisdemethoxy curcumin (BDMC) C3 complex) and the components of the okara mixture obtained by adding soybean curd powder to the curcumin complex were analyzed and compared.
상기 식에서,In the above equation,
커큐민은 R1=OCH3, R2=OCH3, MW=368이고,Curcumin is R 1 =OCH 3 , R 2 =OCH 3 , MW=368,
디메톡시커큐민은 R1=OCH3, R2=H, MW=338이고,Dimethoxycurcumin has R 1 =OCH 3 , R 2 =H, MW=338,
비스디메톡시 커큐민은 R1=H, R2=H, MW=308이다.Bisdimethoxy curcumin has R 1 =H, R 2 =H, MW=308.
구체적으로, 아래와 같이 3가지 종류의 시료를 준비하였다.Specifically, three types of samples were prepared as follows.
(1) 커큐민 복합체 (Curcumin C3 complex, 20 mg) + H2O (200 mL)(1) Curcumin C3 complex (20 mg) + H 2 O (200 mL)
(2) 콩비지 분말 (200 mg) + H2O (200 mL) (2) Okara powder (200 mg) + H 2 O (200 mL)
(3) 콩비지 혼합물 (Curcumin C3 complex (20 mg) + 콩비지 분말 (200 mg)) + H2O (200 mL)(3) Okara mixture (Curcumin C3 complex (20 mg) + Okara powder (200 mg)) + H 2 O (200 mL)
상기 준비된 세 가지의 시료를 35 ℃에서 30분간 교반한 후, 에멀젼 1 mL을 취하여 MeOH 2 mL으로 희석한 다음 HPLC 분석하였다. 또한, 상기 준비된 세 가지의 시료를 35 ℃에서 30분간 교반한 후 초음파 균질기 (ultrasonic homogenizer)로 6,000 rpm으로 2분간 균질화하고, 에멀젼 1 mL을 취하여 MeOH 2 mL으로 희석한 다음 HPLC 분석하였다 (도 1 및 2 참조). HPLC 분석 조건은 아래와 같고, 그 결과를 도 3에 나타내었다.After stirring the three samples prepared above for 30 minutes at 35°C, 1 mL of the emulsion was taken, diluted with 2 mL of MeOH, and then analyzed by HPLC. In addition, the three samples prepared above were stirred at 35°C for 30 minutes, then homogenized with an ultrasonic homogenizer at 6,000 rpm for 2 minutes, and 1 mL of the emulsion was taken, diluted with 2 mL of MeOH, and then analyzed by HPLC (Figure 1 and 2). The HPLC analysis conditions are as follows, and the results are shown in Figure 3.
HPLC 분석 기기명 : Agilent 1200 seriesHPLC analysis device name: Agilent 1200 series
- Degasser: G1322A- Degasser: G1322A
- Pump: G1312A- Pump: G1312A
- Autosampler: G1329A- Autosampler: G1329A
- Column oven: G1316A- Column oven: G1316A
- Detector(DAD): G1315B-Detector(DAD): G1315B
용매 : 0.1% FA in ACN(A), 0.1% FA in Water(B)Solvent: 0.1% FA in ACN(A), 0.1% FA in Water(B)
기울기 : A: 0min(10%)-5min(10%)-40min(100%)-45min(100%)Slope: A: 0min(10%)-5min(10%)-40min(100%)-45min(100%)
컬럼 : YMC ODS-A C18/ 150x4.6mmI.D./ S-5um/ 12nmColumn: YMC ODS-A C18/ 150x4.6mmI.D./ S-5um/ 12nm
컬럼 오븐 : 30 ℃Column oven: 30℃
유동률 : 0.7ml/minFlow rate: 0.7ml/min
주입량 : 10ulInjection amount: 10ul
HPLC monitored : 210, 254, 280, 330, 420 nmHPLC monitored: 210, 254, 280, 330, 420 nm
그 결과, 커큐민 복합체에 콩비지 분말을 첨가할 경우 커큐민 복합체의 화학 성분에 큰 차이를 보이는 것을 확인하였다.As a result, it was confirmed that when okara powder was added to the curcumin complex, there was a significant difference in the chemical composition of the curcumin complex.
실험예Experiment example 2. 2. ADHADH 및 and ALDHALDH 효소 활성 분석 ( Enzyme activity assay ( in vitroin vitro ))
알코올 대사에 관련된 효소인 ADH (Alcohol Dehydrogenase) 및 ALDH (Aldehyde Dehydrogenase)는 Sigma Chemical Co. (Saint Louis, Mo., USA)에서, 동결건조된 S9 rat liver homogenate는 MolTox Co. (North Carolina, USA)에서 구입하여 사용하였다.ADH (Alcohol Dehydrogenase) and ALDH (Aldehyde Dehydrogenase), enzymes involved in alcohol metabolism, were purchased from Sigma Chemical Co. (Saint Louis, Mo., USA), lyophilized S9 rat liver homogenate was purchased from MolTox Co. It was purchased and used in (North Carolina, USA).
ADH 효소 활성 측정은 Alcohol Dehydrogenase Activity Assay Kit (sigma, #MAK053)를 이용하여 제조사에서 제시한 방법에 따라 측정하였다. S9 rat liver fraction을 0.1% bovine serum albumin 용액에 용해시킨 후, 1 mg/mL의 단백질 농도로 제조하여 효소원으로 사용하였다. 시험 시료를 Kit에 포함되어 있는 Reaction mix (ADH assay buffer, Developer, 2M Ethanol)와 반응시켜 37 ℃에서 3시간 동안 1시간 마다 450 nm에서 흡광도의 변화를 측정하였다. ADH의 활성은 반응 종료 시의 최대 흡광도를 대조군의 최대 흡광도에 대한 상대적인 % activity를 구하였다. 이때 시료를 첨가하지 않은 것을 대조군으로 하였다.ADH enzyme activity was measured using the Alcohol Dehydrogenase Activity Assay Kit (sigma, #MAK053) according to the method suggested by the manufacturer. S9 rat liver fraction was dissolved in 0.1% bovine serum albumin solution, prepared at a protein concentration of 1 mg/mL, and used as an enzyme source. The test sample was reacted with the Reaction mix (ADH assay buffer, Developer, 2M Ethanol) included in the kit, and the change in absorbance was measured at 450 nm every hour for 3 hours at 37°C. The activity of ADH was calculated as the relative % activity of the maximum absorbance at the end of the reaction with respect to the maximum absorbance of the control group. At this time, the one in which no sample was added was used as the control group.
ALDH 효소 활성 측정은 Aldehyde Dehydrogenase Activity Colorimetric Assay Kit (sigma, #MAK082)를 이용하여 제조사에서 제시한 방법에 따라 측정하였다. S9 rat liver fraction을 0.1% bovine serum albumin 용액에 용해시킨 후, 1 mg/mL의 단백질 농도로 제조하여 효소원으로 사용하였다. 시험 시료를 Kit에 포함되어 있는 Reaction mix (ALDH assay buffer, ALDH Substrate Mix, Acetaldehyde)와 반응시켜 실온에서 3시간 동안 1시간 마다 450 nm에서 흡광도의 변화를 측정하였다. ALDH 활성은 대조군에 대한 상대 활성 (%)으로 표시하였다. 이때 시료를 첨가하지 않은 것을 대조군으로 하였다.ALDH enzyme activity was measured using the Aldehyde Dehydrogenase Activity Colorimetric Assay Kit (sigma, #MAK082) according to the method suggested by the manufacturer. S9 rat liver fraction was dissolved in 0.1% bovine serum albumin solution, prepared at a protein concentration of 1 mg/mL, and used as an enzyme source. The test sample was reacted with the reaction mix (ALDH assay buffer, ALDH Substrate Mix, Acetaldehyde) included in the kit, and the change in absorbance was measured at 450 nm every hour for 3 hours at room temperature. ALDH activity was expressed as relative activity (%) to the control group. At this time, the one in which no sample was added was used as the control group.
그 결과, ADH 활성이 3시간 대에서 실시예 1 163%, 실시예 2 178% 및 실시예 3 172.1%를 보여 시료 미첨가를 대조군으로서 control을 100%로 하였을 때 시료 모두 ADH 활성이 증가하였으며, 특히 실시예 2 시료에서 ADH 활성이 가장 높게 증가하였다 (도 4 참조).As a result, ADH activity was 163% in Example 1, 178% in Example 2, and 172.1% in Example 3 at 3 hours. When the control was set to 100% as a control group without adding the sample, the ADH activity increased in all samples. In particular, ADH activity increased the most in the sample of Example 2 (see Figure 4).
또한, 시료 미첨가를 대조군으로서 control을 100%로 하였을 때 ALDH 활성이 3시간 대에서 실시예 2 327%로 활성이 가장 촉진되었고, 실시예 1 201%, 실시예 3 305.4%로 활성이 증가함을 확인하였다 (도 5 참조). 실시예 2 시료는 아세트알데히드를 빠르게 분해시켜 숙취 해소 효과를 더욱 증진시키는 효과가 있음을 알 수 있었다.In addition, when control was set to 100% without adding a sample as a control, ALDH activity was most promoted at 3 hours in Example 2 at 327%, and activity increased to 201% in Example 1 and 305.4% in Example 3. was confirmed (see Figure 5). It was found that the Example 2 sample had the effect of quickly decomposing acetaldehyde and further improving the hangover relief effect.
실험예 3. 혈중 알코올 농도, ADH 및 ALDH 효소 활성 분석 (Experimental Example 3. Blood alcohol concentration, ADH and ALDH enzyme activity analysis ( in vivoin vivo ))
(1) 실험동물(1) Laboratory animals
본 실험예에서 사용된 동물은 체중 260 내지 280 g의 생후 7주령 Sprague-Dawley (SD) 수컷 흰쥐를 (주)오리엔트사 (BioOrient Co., Seoul, Korea)에서 구입하여 1주일 동안 고형배합사료와 물로 예비사육시킨 후 체중이 280 내지 300 g에 도달하였을 때 실험을 수행하였다. 사육환경은 온도 25±2℃, 습도 50±5%를 유지시키고 12시간 간격으로 lightcycle을 유지하여 개개의 cage 안에서 사육하였다. 사육하는 동안 식이와 물은 충분히 공급하였다.The animals used in this experimental example were 7-week-old Sprague-Dawley (SD) male rats weighing 260 to 280 g, purchased from BioOrient Co., Seoul, Korea, and fed with solid mixed feed for 1 week. After pre-rearing with water, the experiment was performed when the body weight reached 280 to 300 g. The breeding environment was maintained at a temperature of 25 ± 2°C and humidity of 50 ± 5%, and the animals were reared in individual cages with a light cycle maintained at 12-hour intervals. Sufficient food and water were provided during rearing.
(2) 시료 제공 및 간 손상 유발(2) Providing samples and causing liver damage
실험군은 정상군 (control), 알코올 투여군 (negative control), 실시예 1 투여군, 실시예 2 투여군, 실시예 3 투여군으로 총 5군으로 나누었으며 (표 2), 사료 섭취로 인해 알코올의 흡수 방해 현상을 배재하기 위하여 에탄올 투여 전 18시간 동안 절식시켰다. 각 시험 시료의 투여 방법은 시험 시료를 312 mg/Kg 농도로 D.W (Distilled water)에 조제하여 경구투여하였다. 30분 후 알코올을 3 g/Kg의 양으로 경구투여한 후 1, 3, 5시간에 심장에서 혈액을 채취하였다. 채취한 혈액은 4 M perchloric acid를 가해 최종 농도 1 M이 되게 조절하여 혼합한 후 4 ℃에서 5분 동안 방치한 후 13,000 rpm에서 2분간 냉장 상태로 원심분리하였다. 상등액 100 ul에 2M KOH 34 ul를 혼합하고 pH를 6.5 내지 8.0 사이로 조절한 후 4 ℃에서 30분 동안 방치하였다. 15,000 rpm에서 15분간 냉장 상태로 원심분리하여 단백질을 제거한 후, 상등액을 에탄올 측정 키트 (Sigma, #MAK076)를 이용하여 에탄올 농도를 측정하였다.The experimental group was divided into a total of 5 groups: normal group (control), alcohol administration group (negative control), Example 1 administration group, Example 2 administration group, and Example 3 administration group (Table 2). Alcohol absorption phenomenon was observed due to feed intake. To exclude this, the subjects were fasted for 18 hours before ethanol administration. The method of administration of each test sample was to prepare the test sample in D.W (Distilled water) at a concentration of 312 mg/Kg and administer it orally. After 30 minutes, alcohol was administered orally at an amount of 3 g/Kg, and blood was collected from the heart at 1, 3, and 5 hours. The collected blood was mixed by adding 4 M perchloric acid to a final concentration of 1 M, left at 4°C for 5 minutes, and centrifuged at 13,000 rpm for 2 minutes in refrigerated condition. 34 ul of 2M KOH was mixed with 100 ul of the supernatant, the pH was adjusted to between 6.5 and 8.0, and the mixture was left at 4°C for 30 minutes. After centrifugation at 15,000 rpm for 15 minutes in refrigerated condition to remove proteins, the ethanol concentration of the supernatant was measured using an ethanol measurement kit (Sigma, #MAK076).
(3) 간 조직의 ADH 및 ALDH 활성 측정(3) Measurement of ADH and ALDH activity in liver tissue
간 조직을 해동하여 D-PBS로 3회 세척한 후 조직 무게 (g) 10배의 0.1 M Tris-HCl buffer (pH 7.4)를 가하고 빙냉하에서 분쇄기로 균질화하여 준비하였다. 간 조직 균질액의 ADH와 ALDH 활성은 NAD+ 환원에 따른 NADH 생성량을 비색정량하여 측정하는 방법으로 제조된 assay kit (sigma, #MAK053, sigma, #MAK082)를 사용하여 측정하였고, 각 kit에서 제시한 계산식을 이용하여 milliunits/mL로 제시하였다.The liver tissue was thawed and washed three times with D-PBS, then 10 times the tissue weight (g) of 0.1 M Tris-HCl buffer (pH 7.4) was added and homogenized using a grinder under ice cooling. ADH and ALDH activities of liver tissue homogenates were measured using assay kits (sigma, #MAK053, sigma, #MAK082) manufactured by colorimetrically measuring the amount of NADH produced by NAD+ reduction, and the It was presented in milliunits/mL using the calculation formula.
숙취 개선 효능을 확인하기 위해 Rat에 알코올을 단회 투여하여 1, 3, 5시간 후 혈액을 채취하여 혈중 알코올 농도를 측정하고, 간을 적출하여 ADH 및 ALDH 농도를 측정한 결과를 도 6 내지 8에 나타내었다.To confirm the effectiveness of improving hangovers, a single dose of alcohol was administered to rats, blood was collected 1, 3, and 5 hours later to measure blood alcohol concentration, liver was extracted, and ADH and ALDH concentrations were measured. The results are shown in Figures 6 to 8. indicated.
혈중 알코올 농도는 음주 후 60 내지 90분 사이에 최고치를 나타낸다는 기존 보고와 같이 1시간 만에 혈중 알코올 농도가 최고치에 도달하였다. 에탄올 투여 후 1시간에서는 모든 시료에서 큰 변화가 없었지만, 에탄올 투여 3시간과 5시간에서 대부분의 시료들 모두 알코올 투여군에 비해 혈중 에탄올 농도가 감소하는 것을 확인하였다 (도 6 참조). 특히, 실시예 2 시료는 모든 시간에서 실시예 1 시료보다 혈중 알코올 농도를 더욱 감소시켰으며, 5시간에서 가장 낮은 혈중 알코올 농도를 나타내었다. 실시예 2 시료는 정상군에 비해 0.8배 정도 낮은 혈중 알코올 수치를 나타내었다.Consistent with previous reports that blood alcohol concentration peaks between 60 and 90 minutes after drinking, the blood alcohol concentration reached its peak in just one hour. There was no significant change in all samples at 1 hour after ethanol administration, but at 3 and 5 hours after ethanol administration, it was confirmed that the blood ethanol concentration of most samples decreased compared to the alcohol administration group (see Figure 6). In particular, the Example 2 sample reduced blood alcohol concentration more than the Example 1 sample at all times and showed the lowest blood alcohol concentration at 5 hours. Example 2 The sample showed a blood alcohol level that was about 0.8 times lower than that of the normal group.
ADH 활성은 3시간대에서 가장 높게 나타났으며, 정상군 (control, D.W)은 0.587±0.09 mU/mL, 실험군은 각각 2.687±0.82 mU/mL, 4.559±1.71 mU/mL, 4.105±1.70 mU/mL으로 나타났으며, 실시예 2 및 실시예 3 시료는 정상군보다 약 7.7배 및 6.9배 높은 ADH 활성을 나타내었다 (도 7 참조).ADH activity was highest at 3 hours, with the normal group (control, D.W) being 0.587±0.09 mU/mL and the experimental group being 2.687±0.82 mU/mL, 4.559±1.71 mU/mL, and 4.105±1.70 mU/mL, respectively. It was found that the samples of Examples 2 and 3 showed ADH activity that was about 7.7 and 6.9 times higher than that of the normal group (see Figure 7).
또한, 에탄올 투여에 의해 간 조직의 ALDH 활성이 감소하였으나, 시험 시료의 투여에 따라 2시간대부터 ALDH 활성이 증가하였다. 구체적으로, 실험군은 각각 0.923±0.235 mU/mL, 1.229±0.366 mU/mL, 1.098±0.343 mU/mL의 ALDH 활성을 나타내어 정상군 (control, D.W)의 0.170±0.024 mU/mL보다 각각 5.4배, 7.2배, 6.4배 높은 활성을 나타내었다 (도 8 참조). 특히, 실시예 2 시료는 아세트알데히드를 빠르게 분해시켜 숙취 해소 효과를 더욱 증진시키는 효과가 있음을 확인하였다. 이는 in vitro에서 간 효소 ALDH 활성을 촉진시키는 결과와 일치하였다.In addition, ALDH activity in liver tissue decreased due to ethanol administration, but ALDH activity increased from 2 hours upon administration of the test sample. Specifically, the experimental group showed ALDH activity of 0.923±0.235 mU/mL, 1.229±0.366 mU/mL, and 1.098±0.343 mU/mL, respectively, which was 5.4 times higher than the 0.170±0.024 mU/mL of the normal group (control, D.W). It showed 7.2- and 6.4-fold higher activity (see Figure 8). In particular, it was confirmed that the sample of Example 2 had the effect of quickly decomposing acetaldehyde and further enhancing the hangover relief effect. This was consistent with the results of promoting liver enzyme ALDH activity in vitro.
이상, 본 개시물의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적인 기술은 단지 바람직한 실시 태양일 뿐이며, 이에 의해 본 개시물의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서 본 개시물의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의해 정의된다고 할 것이다.As described above, specific parts of the present disclosure have been described in detail, and it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present disclosure. something to do. Accordingly, the substantial scope of the present disclosure will be defined by the appended claims and their equivalents.
Claims (10)
상기 콩비지 분말은 500 내지 2,000 mesh의 크기를 갖는 것인, 숙취 해소용 조성물.
Contains turmeric extract powder, okara powder, yeast extract powder, corn starch powder, and milk thistle extract powder as active ingredients,
A composition for relieving a hangover, wherein the okara powder has a size of 500 to 2,000 mesh.
상기 조성물은 조성물 전체 중량을 기준으로 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 분말 및 밀크씨슬 추출 분말을 각각 2 내지 5 중량%, 25 내지 40 중량%, 25 내지 40 중량%, 15 내지 25 중량% 및 3 내지 6 중량%로 포함하는 것인, 숙취 해소용 조성물.
According to clause 1,
The composition contains 2 to 5% by weight, 25 to 40% by weight, 25 to 40% by weight, and 15% of turmeric extract powder, okara powder, yeast extract powder, corn starch powder, and milk thistle extract powder, respectively, based on the total weight of the composition. A composition for relieving a hangover, comprising from 25% by weight and 3 to 6% by weight.
상기 조성물은 조성물 전체 중량을 기준으로 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 분말 및 밀크씨슬 추출 분말을 3 내지 4 중량%, 28 내지 31 중량%, 28 내지 31 중량%, 18 내지 23 중량% 및 3 내지 4 중량%로 포함하는 것인, 숙취 해소용 조성물.
According to clause 1,
The composition contains 3 to 4% by weight, 28 to 31% by weight, 28 to 31% by weight, and 18 to 4% by weight of turmeric extract powder, okara powder, yeast extract powder, corn starch powder, and milk thistle extract powder based on the total weight of the composition. A composition for relieving a hangover, comprising 23% by weight and 3 to 4% by weight.
상기 콩비지 분말은 900 내지 1,100 mesh의 크기를 갖는 것인, 숙취 해소용 조성물.
According to clause 1,
A composition for relieving a hangover, wherein the okara powder has a size of 900 to 1,100 mesh.
상기 조성물은 강황 추출 분말, 콩비지 분말, 효모 추출 분말, 옥수수전분 분말 및 밀크씨슬 추출 분말을 1 : 8 내지 10 : 8 내지 10 : 6 내지 8 : 1 내지 2의 중량비로 포함하는 것인, 숙취 해소용 조성물.
According to clause 1,
The composition includes turmeric extract powder, okara powder, yeast extract powder, corn starch powder, and milk thistle extract powder in a weight ratio of 1:8 to 10:8 to 10:6 to 8:1 to 2. Composition for resolving.
상기 조성물은 혈액 내 알코올 함량을 감소시키는 것인, 숙취 해소용 조성물.
According to clause 1,
The composition is a composition for relieving a hangover, which reduces the alcohol content in the blood.
상기 조성물은 알코올탈수소효소 (ADH) 및 알데히드탈수소효소 (ALDH)의 활성을 증진시키는 것인, 숙취 해소용 조성물.
According to clause 1,
The composition is a composition for relieving a hangover, which improves the activity of alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH).
A health supplement for relieving hangovers, comprising the composition for relieving hangovers according to any one of claims 1, 2, and 4 to 8.
상기 건강보조식품은 액상, 환제, 정제, 과립제, 산제 또는 캡슐제 제형을 갖는 것인, 숙취 해소용 건강보조식품.According to clause 9,
The health supplement is a health supplement for relieving a hangover, having a liquid, pill, tablet, granule, powder, or capsule formulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210006874A KR102642811B1 (en) | 2021-01-18 | 2021-01-18 | Composition for relieving hangover based on soybean curd residue micro-powder |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210006874A KR102642811B1 (en) | 2021-01-18 | 2021-01-18 | Composition for relieving hangover based on soybean curd residue micro-powder |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220104496A KR20220104496A (en) | 2022-07-26 |
KR102642811B1 true KR102642811B1 (en) | 2024-03-05 |
Family
ID=82609868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210006874A KR102642811B1 (en) | 2021-01-18 | 2021-01-18 | Composition for relieving hangover based on soybean curd residue micro-powder |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102642811B1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1893933A (en) | 2003-11-19 | 2007-01-10 | 奥加生物药业(I.P.1)有限公司 | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
CN101528240A (en) | 2006-10-16 | 2009-09-09 | 宝生物工程株式会社 | Activity enhancer for detoxifying enzyme |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100903690B1 (en) | 2007-12-18 | 2009-06-18 | 주식회사 엠에이치투 바이오케미칼 | Composition containing ornithine for relieving hang-over and alcohol liquor containing ornithine |
KR20140026737A (en) * | 2012-08-23 | 2014-03-06 | 한국인스팜(주) | A composition comprising the powder of fermented curcuma longa l. for protecting alcoholic liver damage |
KR101525478B1 (en) * | 2013-09-06 | 2015-06-03 | 한미약품 주식회사 | Food composition for relieving hangover |
KR101865360B1 (en) * | 2015-07-15 | 2018-06-07 | 주식회사 유니베라 | Compositions and medical compositions for treatment of and maintaining the health of the liver |
KR102648340B1 (en) * | 2018-04-30 | 2024-03-18 | 동아제약 주식회사 | Composition for hepatoprotective activity comprising Turmeric extract solution and Rice Soybean extract |
-
2021
- 2021-01-18 KR KR1020210006874A patent/KR102642811B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1893933A (en) | 2003-11-19 | 2007-01-10 | 奥加生物药业(I.P.1)有限公司 | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
CN100391448C (en) | 2003-11-19 | 2008-06-04 | 奥加生物药业(I.P.1)有限公司 | Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers |
CN101528240A (en) | 2006-10-16 | 2009-09-09 | 宝生物工程株式会社 | Activity enhancer for detoxifying enzyme |
Non-Patent Citations (2)
Title |
---|
J Med Food vol.12(6), pp.1359-1367(2009.12.30.) |
유재영 외 5명, Effects of DA-5513 on alcohol metabolism and alcoholic fatty liver in rats, Lab Anim Res Vol. 34, No. 2, 2018년 6월* |
Also Published As
Publication number | Publication date |
---|---|
KR20220104496A (en) | 2022-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2934344T3 (en) | Method for the simultaneous production of ethanol and a solid fermented product | |
CN104982928B (en) | A kind of japanese yew fruit health care ferment and preparation method thereof | |
CN104905158B (en) | Marx-kluyveromyces fermented soybean dregs powder | |
KR101793123B1 (en) | preparing method of fermented soybean enhancing physiological active substance and the physiological active substance thereby | |
KR20140137549A (en) | A EXTRACTING METHOD Hovenia dulcis FOR ACTIVATING ALCOHOL METABOLISM AND RELIEVING A HANGOVER AND HEALTHY FUNCTIONAL FOOD CONTAINING THE SAME | |
KR20110038758A (en) | Composition containing ginsenosides rg3 and rg2 to improve exercise capacity and fatigue recuperation | |
KR101238968B1 (en) | Method for preparing composition comprising fermented wild ginseng that contain ergothioneine | |
Gutiérrez-Macías et al. | Cocoa: Beyond chocolate, a promising material for potential value-added products | |
JP5993112B2 (en) | Antidepressant | |
KR101100337B1 (en) | Manufacturing method of granular tea using Phellinus linteus | |
KR101040716B1 (en) | Feed additives using orostachys japonicus and feed composition, functional egg | |
KR102642811B1 (en) | Composition for relieving hangover based on soybean curd residue micro-powder | |
CN111919976A (en) | Feed additive for rabbits and application and preparation method thereof | |
KR20120106218A (en) | Manufacturing method of treated puffing and fermentation red ginseng concentrate | |
KR20160047169A (en) | Composition for reducing methane in ruminants and feed comprising the same | |
KR101045011B1 (en) | Method for preparing composition comprising fermented by using of hippophae rhamnoides l | |
KR102159821B1 (en) | Fermented feed composition for ruminant and manufacturing method thereof | |
KR101620939B1 (en) | Method for preparing antiobese natural fermented vinegar using dendropanax morbiferum leveille and pear | |
KR102008615B1 (en) | Preparation method of Mixed Liquid Sticks using Agar Peach Extracts fermented by Saccharification and Yeast Fermentation with Osmotic pressure | |
KR101291388B1 (en) | Crude Saponin Mixture Extracted from Fermentation Mixture of Soybean and Ginseng Having a Functionality for Hangover and It's Preparation Methods | |
KR20160058201A (en) | Manufacturing method of ginseng leaves powder cultured by hydroponics and ginseng leaves powder thereof | |
KR101228554B1 (en) | The Fermentation Forming Method of Citrus Sunki And The Product thereof | |
CN111903840A (en) | Compound ginkgo leaf feed additive rich in probiotics | |
KR20190014858A (en) | A fermented grain and method fot preparing thereof | |
KR101151706B1 (en) | Anti-oxidative feed composition comprising hempseed extract for fruit fly and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |